NEW YORK — Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, has emerged from stealth and the signing of its first co-development and supply agreement with a major global pharmaceutical company. Neion’s Raptor platform utilizes the latest genetic engineering tools to produce recombinant biologics in eggs, enabling scalable and efficient production of virtually any therapeutic protein. This commercial deal provides Neion with near-term revenue through up-front and milestone payments, along with long-term participation through profit sharing once products are commercialized.
The company launched in 2024 with approximately $11 million in financing from a consortium of venture capital firms led by Caffeinated Capital with significant participation from Basis Set Ventures and Haystack VC, among others.
“Biopharma manufacturing has not changed in decades, and has become a major bottleneck in advancing medical breakthroughs, increasing accessibility of existing therapies, and localizing domestic production of critical medicines,” said Dimi Kellari, co-founder and CEO of Neion Bio. “Neion Bio’s platform removes the capital intensity and process constraints of traditional biomanufacturing enabling highly scalable and resilient production while materially lowering the cost of development and supply.”
Neion’s Raptor platform harnesses nature’s most powerful molecular factory – the egg – to create a highly reproducible and consistent manufacturing process. Neion re-engineers these self-contained, naturally sterile vesicles to produce virtually any biological therapeutic at an order of magnitude lower costs. The Raptor™ platform enables consistent protein expression, simplified operations, and a level of manufacturing control that is difficult to achieve in traditional cell-culture-based manufacturing. The platform is made possible by recent advances in precision genome engineering, the availability of large genomic data sets, and the ability to grow avian primordial germ cells (“PGCs”).
“Millions of years of evolution have sculpted this system into an extremely prolific producer of complex proteins. By leveraging this natural architecture, we’ve created a fundamentally superior way to produce biological therapeutics,” said Dr. Sam Levin, co-founder and CTO of Neion Bio. “Our platform delivers improved control and scalability versus conventional biomanufacturing without the burden and cost of large steel tanks or disposable plastics. As AI dramatically reduces the time and cost to design breakthrough medicines, we are enabling a pathway to bring these to market far more efficiently and sustainably than traditional manufacturing.”
